ClinicalTrials.gg
Enrolling by invitationNCT07223138Updated Nov 12, 2026

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

A Phase 3 interventional study of Sonelokimab in Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics AG. Enrolling by invitation at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by MoonLake Immunotherapeutics AG · Phase 3, Interventional, and Treatment

Updated Nov 12, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,560
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Planned enrollment
4th of 158
1,560 · median 237
Started
2025
with 13 others
Phase 3
71 of 193
4 open now
Primary completion
2028-02
later than 42 of 58 live
Registered
184th of 193
by date

Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 4th largest by planned enrollment of the 158 interventional ones that give a count, is one of 14 that started in 2025, is one of 71 in phase 3, reaches primary completion later than 42 of the 58 other live ones, and was the 184th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)

Read the detailed description

M1095-PSA-303 is a Phase 3, multicenter, open-label extension study to investigate the long-term safety, tolerability and clinical efficacy of sonelokimab 60 mg subcutaneously every 4 weeks in patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302).

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

Keywords

  • Anti-Inflammatory Agents
  • Sonelokimab
  • Nanobody
  • Psoriatic Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who, in the opinion of the investigator, are expected to benefit from participation in this OLE study.
  2. Participants who have received the second to last and/or last dose, as planned in the parental study, and have completed the end-of-treatment visit of the parental study.
  3. Participants must have received their last dose of study treatment in the parental study no more than 8 weeks (but ideally 4 weeks) before the first dose in this OLE study.
  4. Female participants are eligible to participate if they are not pregnant or breastfeeding and must be of nonchildbearing potential or must agree to use highly effective methods of during the study and for at least 8 weeks after the last dose of study treatment. Female participant of must refrain from donating oocytes during the study and for at least 8 weeks after the last dose of study treatment.
  5. Male participants must be willing to use a condom when sexually active with a partner of childbearing potential during the study and for at least 8 weeks after the last dose of study treatment, unless surgically sterile. Male participants must also agree to refrain from donating sperm during the study and for at least 8 weeks after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Participants who met any of the discontinuation criteria of the parental study at the time of enrollment in this OLE study.
  2. Participants who have ongoing or planned use of one or more of the prohibited PsA or non-PsA treatments specified in this protocol.
  3. Participants who plan to participate in another interventional study for a drug or device during this study.
  4. Participants who were unblinded during the parental study.
  5. Participant noncompliance to the parental study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,560 participants (estimated)

Study arms

  • Experimental
    Experimental: sonelokimab dose

    All participants will receive sonelokimab subcutaneously every 4 weeks

    Drug: Sonelokimab

Interventions

06

What researchers measure

Primary outcomes

  1. Long-term safety and tolerability of sonelokimab:

    Treatment-emergent adverse events (TEAEs)

    Time frame: 52 weeks

  2. Long-term safety and tolerability of sonelokimab:

    Serious adverse events (SAEs)

    Time frame: 52 weeks

  3. Long-term safety and tolerability of sonelokimab:

    TEAEs leading to study withdrawal

    Time frame: 52 weeks

  4. Long-term safety and tolerability of sonelokimab:

    Adverse events of special interest (AESIs)

    Time frame: 52 weeks

  5. Long-term safety and tolerability of sonelokimab:

    Clinically significant changes in vital signs and standard 12-lead electrocardiogram Measure description: Number of participants with clinically significant changes in vital signs and 12-lead ECG intervals from baseline

    Time frame: 52 weeks

  6. Long-term safety and tolerability of sonelokimab:

    Clinically significant changes in clinical laboratory parameters Measure description: Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline

    Time frame: 52 weeks

Secondary outcomes

  1. Long-term efficacy of sonelokimab:

    Proportion of participants achieving American College of Rheumatology (ACR) 20/50/70% improvement criteria over time

    Time frame: 52 weeks

  2. Long-term efficacy of sonelokimab:

    Change over time in Minimal disease activity (MDA)

    Time frame: 52 weeks

  3. Long-term efficacy of sonelokimab:

    Change over time in Health assessment questionnaire-disability index (HAQ-DI)

    Time frame: 52 weeks

  4. Long-term efficacy of sonelokimab:

    Change over time in Tender joint count (TJC)68/ swollen joint count (SJC)66

    Time frame: 52 weeks

  5. Long-term efficacy of sonelokimab:

    Proportion of participants achieving Psoriasis Area and Severity Index (PASI) 75/90/100 over time

    Time frame: 52 weeks

  6. Long-term efficacy of sonelokimab:

    Change over time in Modified Nail Psoriasis Severity Index (mNAPSI)

    Time frame: 52 weeks

  7. Long-term efficacy of sonelokimab:

    Proportion of participants achieving Very low disease activity (VLDA) over time

    Time frame: 52 weeks

  8. Long-term efficacy of sonelokimab:

    Proportion of participants achieving SpondyloArthritis Research Consortium of Canada (SPARCC) over time

    Time frame: 52 weeks

  9. Long-term efficacy of sonelokimab:

    Change over time in Leeds Enthesitis Index (LEI)

    Time frame: 52 weeks

  10. Long term efficacy of sonelokimab

    Proportion of participants achieving both an ACR 50/ACR70 and PASI90/100 improvement over time

    Time frame: 52 weeks

07

Study locations

18 sites
  • Clinical Site
    Avondale, Arizona 85392, United States
  • Clinical Site
    Mesa, Arizona 85210, United States
  • Clinical Site
    Phoenix, Arizona 85032, United States
  • Clinical Site
    Scottsdale, Arizona 85260, United States
  • Clinical Site
    Tucson, Arizona 85748, United States
  • Clinical Site
    Jonesboro, Arkansas 72401, United States
  • Clinical Site
    Upland, California 91786, United States
  • Clinical Site
    Avon Park, Florida 33825, United States
  • Clinical Site
    Clearwater, Florida 33765, United States
  • Clinical Site
    Tampa, Florida 33607, United States
  • Clinical Site
    Baltimore, Maryland 21224-6821, United States
  • Clinical Site
    Charlotte, North Carolina 28262, United States
  • Clinical Site
    Leland, North Carolina 28451, United States
  • Clinical Site
    Middleburg Heights, Ohio 44130, United States
  • Clinical Site
    Duncansville, Pennsylvania 16635, United States
  • Clinical Site
    Memphis, Tennessee 38119, United States
  • Clinical Site
    Baytown, Texas 77521, United States
  • Clinical Site
    Lubbock, Texas 79424, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2028, 26 months after the start.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 26 months is close to that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2025
First posted
Oct 31, 2025
StartActual
Nov 13, 2025
Primary completionEst.
Feb 4, 2028
CompletionEst.
Feb 4, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Clinical Site · Baltimore, United States
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added
    Show site
    • Clinical Site · Baltimore, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07223138
Lead sponsor
MoonLake Immunotherapeutics AG
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Nov 13, 2025
Primary completion
Feb 4, 2028 (estimated)
Completion
Feb 4, 2028 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonelokimab

Start the discussion